London Unit Scoops Leading Research Award - Applied Clinical Trials


See our 2013 Buyers Guide Digital Edition.
London Unit Scoops Leading Research Award

Source: Applied Clinical Trials

The MRC Clinical Trials Unit at University College London has won the top research prize at the 2014 BMJ Awards for its trial treating HIV-positive babies and children in the Uganda and Zimbabwe.

The facility’s Antiretroviral Research for Watoto (ARROW) Trial Team aims to achieve universal coverage of antiretroviral therapy (ART) for young children with HIV from poor populations. More than 330,000 children worldwide were newly infected in 2011, and greater efforts to expand HIV treatment programs are essential, according to researchers from the unit. ART is lifesaving for children, and early diagnosis and treatment reduce mortality and HIV progression by 75%, but large and rigorous trials of pediatric HIV treatment are rare, they noted.

The judges believe that by addressing this neglected population, ARROW has greatly expanded knowledge base to improve treatment for children with HIV. They agree that uncertainties about treatment strategies and monitoring should not undermine efforts to strengthen rollout of ART for children. ARROW provides a clear demonstration that excellent clinical outcomes can be attained in children with HIV despite resource constraints that mar efforts to manage HIV in the settings most affected by this devastating epidemic, they stated.

The group published the following article about its work in NEJM on 2 January 2014: A Randomized Trial of Prolonged Co-trimoxazole in HIV-Infected Children in Africa, by Mutsawashe Bwakura-Dangarembizi et al (n engl j med 370;1).

Read the full release here.


blog comments powered by Disqus



8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here